Henrique Jannuzzelli Pires Do Prado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Henrique Jannuzzelli Pires Do Prado has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Isabella D'ANdrea Meira
Department of Neurology Yale School of Medicine New Haven Connecticut USA
2 shared publications - Abraão Iuri Medeiros Angelim
Instituto Estadual do Cérebro Paulo Niemeyer, Departamento de Epilepsia, Rio de Janeiro RJ, Brazil
1 shared publication - Alexandre Ribeiro Fernandes
Hospital Regional de Presidente Prudente, Presidente Prudente SP, Brazil
1 shared publication - Daniela Fontes Bezerra
Department of Epilepsy Faculdade de Medicina do ABC São Paulo Brazil
1 shared publication - Fernanda Veiga de Goes
Department of Child Neurology, Instituto Nacional de Saúde da Mulher, Criança e do adolescente Fernandes Figueira (IFF) – Fiocruz, Rio de Janeiro, Brazil
1 shared publication - Jonadab Dos Santos Silva
Department of Neurology, Icahn School of Medicine at Mount Sinai
1 shared publication
Latest Publications
- Open Access
- 19 January 2026
- Published by Wiley in Epileptic Disorders
- Vol. 28 (1) , 142-154
Efficacy of vagus nerve stimulator during transition to adulthood in patients with treatment‐resistant epilepsy
Objective: To evaluate the efficacy of vagus nerve stimulation (VNS) as an adjunctive treatment in pediatric patients with treatment‐resistant epilepsy during the transition to adolescence. Methods: We performed a retrospective cohort study of 30 children (ages 2–18 years) with medication‐resistant epilepsy who underwent VNS implantation between January 2019 and January 2023 at a tertiary epilepsy center. Clinical data included demographics, epilepsy etiology and syndrome, age at implantation, seizure frequency and severity (McHugh classification), number of antiseizure medications (ASM), magnet use, and EEG findings. Outcomes were assessed at the last available follow‐up, with a minimum duration of 12 months post‐implantation. Statistical analyses comprised chi‐squared or Fisher's exact tests, Spearman rank correlation, and logistic regression; significance was set at p < 0.05. Results: At the last follow‐up, 20 of 30 patients (66.7%) achieved ≥50% reduction in seizure frequency, and 73% of patients experienced a significant decrease in seizure severity. Status epilepticus (SE) incidence fell from 67% pre‐VNS to 17% post‐VNS ( p = 0.024). The number of ASMs decreased in 57% of patients. Successful magnet activation strongly predicted responder status (OR 10.8, 95% CI 1.2–95.4; p = 0.024). Among females, 12 of 16 (75%) experienced a transient seizure worsening around menarche. Earlier VNS implantation correlated with better seizure reduction (ρ = −0.43; p = 0.015). EEG improvement—defined as reduced interictal epileptiform activity or background normalization—was observed in 23% of patients, predominantly in males and pre‐menarche females. Significance: VNS is an effective adjunctive therapy in pediatric treatment‐resistant epilepsy, yielding substantial reductions in seizure frequency and severity, lowering status epilepticus risk, and simplifying medication regimens. Pubertal status and magnet responsiveness modulate outcomes. Early VNS intervention and proactive management during adolescence may optimize therapeutic benefit.
- 19 January 2026
- Published by Wiley in Epileptic Disorders
- Vol. 28 (1) , 142-154
Open AccessEfficacy of vagus nerve stimulator during transition to adulthood in patients with treatment‐resistant epilepsy
Objective: To evaluate the efficacy of vagus nerve stimulation (VNS) as an adjunctive treatment in pediatric patients with treatment‐resistant epilepsy during the transition to adolescence. Methods: We performed a retrospective cohort study of 30 children (ages 2–18 years) with medication‐resistant epilepsy who underwent VNS implantation between January 2019 and January 2023 at a tertiary epilepsy center. Clinical data included demographics, epilepsy etiology and syndrome, age at implantation, seizure frequency and severity (McHugh classification), number of antiseizure medications (ASM), magnet use, and EEG findings. Outcomes were assessed at the last available follow‐up, with a minimum duration of 12 months post‐implantation. Statistical analyses comprised chi‐squared or Fisher's exact tests, Spearman rank correlation, and logistic regression; significance was set at p < 0.05. Results: At the last follow‐up, 20 of 30 patients (66.7%) achieved ≥50% reduction in seizure frequency, and 73% of patients experienced a significant decrease in seizure severity. Status epilepticus (SE) incidence fell from 67% pre‐VNS to 17% post‐VNS ( p = 0.024). The number of ASMs decreased in 57% of patients. Successful magnet activation strongly predicted responder status (OR 10.8, 95% CI 1.2–95.4; p = 0.024). Among females, 12 of 16 (75%) experienced a transient seizure worsening around menarche. Earlier VNS implantation correlated with better seizure reduction (ρ = −0.43; p = 0.015). EEG improvement—defined as reduced interictal epileptiform activity or background normalization—was observed in 23% of patients, predominantly in males and pre‐menarche females. Significance: VNS is an effective adjunctive therapy in pediatric treatment‐resistant epilepsy, yielding substantial reductions in seizure frequency and severity, lowering status epilepticus risk, and simplifying medication regimens. Pubertal status and magnet responsiveness modulate outcomes. Early VNS intervention and proactive management during adolescence may optimize therapeutic benefit.
- Open Access
- 1 November 2022
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 80 (11) , 1090-1096
Use of lacosamide in children: experience of a tertiary medical care center in Brazil
Background Lacosamide (LCM) is a third-generation anti-seizure drug approved in Europe and the United States, either as a monotherapy or adjunctive therapy, to treat partial-onset seizures in adults, adolescents, and children. In Brazil, LCM is licensed for treatment only in patients older than 16 years of age. Objective To evaluate a cohort of children presenting with refractory epilepsy who received LCM as an add-on therapy and observe the response and tolerability to the LCM treatment. Methods A retrospective cohort study conducted in a tertiary health care facility, which included 26 children, aged up to 16 years, who presented with refractory epilepsy and received LCM as an add-on treatment. The follow-up visits were scheduled every 3 months until 9 months of treatment with LCM. Results After 3 months of LCM administration, in 73.1% of the children, there was a reduction of > 50% in the frequency of seizures, and this clinical improvement was maintained in most patients (73.9%) for the following 9 months. Mild (such as, somnolence and behavioral changes) or severe (seizure worsening) adverse effects were observed in two and three children respectively. Among responders to LCM, there was a higher prevalence of males, fewer concomitant anti-seizure drugs, and lower percentage of patients using sodium channel blockers. Conclusions Lacosamide should be considered as an early treatment option in pediatric patients with refractory epilepsy, mainly focal seizures.
- 1 November 2022
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 80 (11) , 1090-1096
Open AccessUse of lacosamide in children: experience of a tertiary medical care center in Brazil
Background Lacosamide (LCM) is a third-generation anti-seizure drug approved in Europe and the United States, either as a monotherapy or adjunctive therapy, to treat partial-onset seizures in adults, adolescents, and children. In Brazil, LCM is licensed for treatment only in patients older than 16 years of age. Objective To evaluate a cohort of children presenting with refractory epilepsy who received LCM as an add-on therapy and observe the response and tolerability to the LCM treatment. Methods A retrospective cohort study conducted in a tertiary health care facility, which included 26 children, aged up to 16 years, who presented with refractory epilepsy and received LCM as an add-on treatment. The follow-up visits were scheduled every 3 months until 9 months of treatment with LCM. Results After 3 months of LCM administration, in 73.1% of the children, there was a reduction of > 50% in the frequency of seizures, and this clinical improvement was maintained in most patients (73.9%) for the following 9 months. Mild (such as, somnolence and behavioral changes) or severe (seizure worsening) adverse effects were observed in two and three children respectively. Among responders to LCM, there was a higher prevalence of males, fewer concomitant anti-seizure drugs, and lower percentage of patients using sodium channel blockers. Conclusions Lacosamide should be considered as an early treatment option in pediatric patients with refractory epilepsy, mainly focal seizures.